CANCER CHEMOTHERAPY AND DRUG METABOLISM
Open Access
- 13 July 2005
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 33 (8), 1083-1096
- https://doi.org/10.1124/dmd.105.004374
Abstract
Drug-metabolizing enzymes and drug transporters are key determinants of the pharmacokinetics and pharmacodynamics of many antineoplastic agents. Metabolism and transport influence the cytotoxic effects of antineoplastic agents in target tumor cells and normal host tissues. This article summarizes several state-of-the-art approaches to enhancing the effectiveness and safety of cancer therapy based on recent developments in our understanding of antineoplastic drug metabolism and transport. Advances in four interrelated research areas presented at a recent symposium sponsored by the Division for Drug Metabolism of the American Society for Pharmacology and Experimental Therapeutics (Experimental Biology 2004; Washington D.C., April 17–21, 2004) are discussed: 1) interactions of anthracyclines with drug-metabolizing enzymes; 2) use of hypoxia-selective gene-directed enzyme prodrug therapy (GDEPT) in combination with bioreductive prodrugs; 3) synergy between glutathione conjugation and conjugate efflux in conferring resistance to electrophilic toxins; and 4) use of cytochromes P450 as prodrug-activating enzymes in GDEPT strategies. A clear theme emerged from this symposium: drug metabolism and transport processes can be modulated and exploited in ways that may offer distinct therapeutic advantages in the management of patients with cancer.Keywords
This publication has 50 references indexed in Scilit:
- Role of Multidrug Resistance Protein 2 (MRP2, ABCC2) in Alkylating Agent Detoxification: MRP2 Potentiates GlutathioneS-Transferase A1-1-Mediated Resistance to Chlorambucil CytotoxicityJournal of Pharmacology and Experimental Therapeutics, 2003
- Hypoxia-mediated tumour targetingGene Therapy, 2003
- Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgeneCancer, 2002
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Alterations in expression of CYPlA1 and NADPH-cytochrome P450 reductase during lung tumor development in SWR/J miceCarcinogenesis: Integrative Cancer Research, 1996
- Lack of effect of methotrexate on the expression of constitutive hepatic cytochromes P450 in the male ratXenobiotica, 1996
- The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.British Journal of Clinical Pharmacology, 1995
- The Glut athione S-Transferase Supergene Family: Regulation of GST and the Contribution of the lsoenzymes to Cancer Chemoprotection and Drug Resistance Part ICritical Reviews in Biochemistry and Molecular Biology, 1995
- The effects of adriamycin in vitro and in vivo on hepatic microsomal drug-metabolizing enzymes: Role of microsomal lipid peroxidationToxicology and Applied Pharmacology, 1981
- Depression of cytochrome P-450-dependent drug biotransformation by adriamycinToxicology and Applied Pharmacology, 1981